Trump orders review of childhood vaccine schedule

President Donald Trump signed an executive order Friday directing federal agencies to review and revise the recommended childhood vaccination schedule, aiming to reduce the number of universally recommended vaccines and separate the combined measles, mumps, and rubella (MMR) vaccine into individual shots.

The move follows years of amplified skepticism around vaccines among some of Trump’s supporters, amplified during the COVID-19 pandemic when misinformation spread rapidly. While Trump has previously expressed support for vaccines in general, his administration has faced pressure from anti-vaccine advocacy groups and some Republican lawmakers who argue for greater parental choice over medical decisions. Public health experts warn that altering the schedule could disrupt decades of proven disease prevention strategies and increase risks of outbreaks.

Under current U.S. guidelines from the Centers for Disease Control and Prevention (CDC), children receive up to 16 doses of seven different vaccines by age 18, including MMR at 12–15 months and again at 4–6 years. The new order directs agencies like the Department of Health and Human Services to evaluate whether the list can be shortened or modified. It also calls for studies on the safety and feasibility of separating the MMR vaccine into individual components, which are currently combined for efficiency and lower discomfort in children.

Health officials and medical groups, including the American Academy of Pediatrics, have already criticized the directive, calling it medically unnecessary and potentially dangerous. The order does not immediately change vaccine mandates, which are set by states for school entry, but it signals a federal shift that could embolden local efforts to weaken immunization requirements. Public health advocates warn this could lead to lower vaccination rates, citing recent increases in measles cases in communities with declining coverage. The order also sets the stage for further federal challenges to vaccine policies as the 2024 election approaches, potentially reshaping public health governance under a second Trump term.